Drug Trial Radar · NCT06181227
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
21
Actual
Start
Nov 30, 2023
Primary completion
Apr 5, 2024
Study completion Apr 5, 2024
Sponsor
- Lead sponsor
- Aviceda Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.
Conditions
- Diabetic Macular Edema
- Diabetic Retinopathy
Interventions
AVD-104Drug
An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Serious Adverse EventsTime frame: 3 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Erie Retina Research
Erie, Pennsylvania
Texas Retina Associates
Dallas, Texas
West Texas Retina Consultants
Wichita Falls, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.